MEI Pharma Inc. has become the first U.S.-listed public company to adopt litecoin ( $LTC) as a primary reserve asset, deploying $100 million from a recent stock sale to acquire 929,548 tokens of the cryptocurrency.
Litecoin Creator Charlie Lee Joins MEI Pharma’s Board
The clinical-stage biopharmaceutical company (Nasdaq: MEIP) disclosed the $LTC acquisition in an Aug. 5 regulatory filing. MEI Pharma purchased the litecoin ( $LTC) tokens at an average price of $107.58 between July 30 and Aug. 4, 2025. The investment utilized all net proceeds from a private placement of common stock and warrants completed on July 17.
MEI Pharma’s litecoin holdings were valued at approximately $110.4 million as of Aug. 4. The company described the move as launching a “major institutional treasury strategy” built on “digital asset infrastructure and long-term capital innovation.” The plan was first revealed in mid-July.
news.bitcoin.com